Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUGMENT-102: Revumenib + Chemotherapy in R/R Acute Leukemias
NCT05326516Phase 1Completed
- Sponsor
- Syndax Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of revumenib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia (MPAL) and 1 more (2 arms), sponsored by Syndax Pharmaceuticals. Primary endpoints: Number of Participants With Dose Limiting Toxicities From Revumenib and Number of Participants With Treatment-emergent Adverse Events. Started Mar 2022; status: completed.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)acute undifferentiated leukemia (AUL)
Beyond the preview
Go deeper on NCT05326516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05326516.